FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2133176615> ?p ?o ?g. }

• W2133176615 endingPage "646" @default.
• W2133176615 startingPage "638" @default.
• W2133176615 abstract "To update French Society for Rheumatology guidelines regarding the use of tumor necrosis factor alpha (TNFalpha) antagonists for treating patients with ankylosing spondylitis (AS) or psoriatic arthritis (PsA).We used the method recommended by Shekelle et al. to update the original recommendations: a limited group of experts selected the items that required updating, the relevant literature was critically appraised, and the experts developed new wording for the recommendations, which was then subjected to internal and external validation. As with the original recommendations, three topics were addressed, namely, indications of TNFalpha antagonist therapy, treatment initiation, and treatment adjustment and follow-up.Four criteria should be used to evaluate the indication of TNFalpha antagonist therapy. First, the patient must have a definitive diagnosis of AS or PsA. Thus, patients with AS must meet modified New York criteria or exhibit characteristic involvement of the sacroiliac joints, spine, or peripheral sites documented by radiographs or computed tomography (structural damage) or by magnetic resonance imaging (inflammation). Patients with PsA must meet validated criteria such as the Moll and Wright or CASPAR criteria. The second criterion is active disease for more than 1month, with a BASDAI >or=4 in patients with predominantly axial disease or a tender/swollen joint count >or=3, and with a physician assessment of disease activity of >or=4/10. The third criterion is failure of at least three non-steroidal anti-inflammatory drugs in patients with axial disease or of disease-modifying antirheumatic drug (DMARD) therapy (methotrexate, salazopyrine, or leflunomide) in patients with peripheral disease. Fourth, the patient must be free of contraindications to TNFalpha antagonist therapy. Four recommendations pertain to the initiation of TNFalpha antagonist therapy: a workup should be performed prior to treatment initiation; there is no evidence that one TNFalpha antagonist is more effective than the others, so decisions about drug selection should be shared with the patient and guided by available safety data and the patient's profile; there is no proof that greater effectiveness can be achieved by routinely combining a conventional DMARD; and patients should receive regular standardized follow-up. The last four recommendations deal with adjusting TNFalpha antagonist therapy: the treatment objective is a 2-point or greater improvement in the BASDAI in patients with axial disease and a 30% or greater improvement in the tender/swollen joint counts in patients with peripheral disease; there is no evidence to support the introduction of DMARD therapy in non-responders, who can be switched to another TNFalpha antagonist or, when on infliximab, given higher dosages or more closely spaced injections; patients who fail to tolerate one TNFalpha antagonist can be switched to another TNFalpha antagonist if allowed by the nature of the adverse event; and when a remission is achieved, reduction or discontinuation of concomitant anti-inflammatory therapy should be considered, followed in the event of a prolonged remission by a reduction in the dosage of the TNFalpha antagonist." @default.
• W2133176615 created "2016-06-24" @default.
• W2133176615 creator A5005178337 @default.
• W2133176615 creator A5005853606 @default.
• W2133176615 creator A5008811878 @default.
• W2133176615 creator A5015032522 @default.
• W2133176615 creator A5017486273 @default.
• W2133176615 creator A5022620505 @default.
• W2133176615 creator A5031211618 @default.
• W2133176615 creator A5032316254 @default.
• W2133176615 creator A5047641886 @default.
• W2133176615 creator A5049309445 @default.
• W2133176615 creator A5050180409 @default.
• W2133176615 creator A5051196993 @default.
• W2133176615 creator A5057460230 @default.
• W2133176615 creator A5057763735 @default.
• W2133176615 creator A5068131579 @default.
• W2133176615 creator A5068328534 @default.
• W2133176615 creator A5073579921 @default.
• W2133176615 creator A5076446601 @default.
• W2133176615 date "2007-12-01" @default.
• W2133176615 modified "2023-10-18" @default.
• W2133176615 title "Recommendations of the French Society for Rheumatology regarding TNFα antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update" @default.
• W2133176615 cites W1964651200 @default.
• W2133176615 cites W1966756689 @default.
• W2133176615 cites W1968958817 @default.
• W2133176615 cites W1979060964 @default.
• W2133176615 cites W1986200978 @default.
• W2133176615 cites W1994277369 @default.
• W2133176615 cites W2004546602 @default.
• W2133176615 cites W2010656216 @default.
• W2133176615 cites W2017883234 @default.
• W2133176615 cites W2018697945 @default.
• W2133176615 cites W2021529856 @default.
• W2133176615 cites W2024329087 @default.
• W2133176615 cites W2026178764 @default.
• W2133176615 cites W2046549669 @default.
• W2133176615 cites W2047330557 @default.
• W2133176615 cites W2060702171 @default.
• W2133176615 cites W2074085679 @default.
• W2133176615 cites W2074940911 @default.
• W2133176615 cites W2083180635 @default.
• W2133176615 cites W2085780540 @default.
• W2133176615 cites W2096922032 @default.
• W2133176615 cites W2097730524 @default.
• W2133176615 cites W2100675242 @default.
• W2133176615 cites W2102829569 @default.
• W2133176615 cites W2107510226 @default.
• W2133176615 cites W2108278277 @default.
• W2133176615 cites W2114392365 @default.
• W2133176615 cites W2119046820 @default.
• W2133176615 cites W2124332978 @default.
• W2133176615 cites W2131882149 @default.
• W2133176615 cites W2133606090 @default.
• W2133176615 cites W2133696182 @default.
• W2133176615 cites W2145778588 @default.
• W2133176615 cites W2145837408 @default.
• W2133176615 cites W2149118348 @default.
• W2133176615 cites W2163493960 @default.
• W2133176615 cites W2168698481 @default.
• W2133176615 cites W2170050330 @default.
• W2133176615 cites W2170446962 @default.
• W2133176615 cites W4211046919 @default.
• W2133176615 doi "https://doi.org/10.1016/j.jbspin.2007.10.003" @default.
• W2133176615 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18065252" @default.
• W2133176615 hasPublicationYear "2007" @default.
• W2133176615 type Work @default.
• W2133176615 sameAs 2133176615 @default.
• W2133176615 citedByCount "99" @default.
• W2133176615 countsByYear W21331766152012 @default.
• W2133176615 countsByYear W21331766152013 @default.
• W2133176615 countsByYear W21331766152014 @default.
• W2133176615 countsByYear W21331766152015 @default.
• W2133176615 countsByYear W21331766152016 @default.
• W2133176615 countsByYear W21331766152017 @default.
• W2133176615 countsByYear W21331766152018 @default.
• W2133176615 countsByYear W21331766152020 @default.
• W2133176615 countsByYear W21331766152021 @default.
• W2133176615 crossrefType "journal-article" @default.
• W2133176615 hasAuthorship W2133176615A5005178337 @default.
• W2133176615 hasAuthorship W2133176615A5005853606 @default.
• W2133176615 hasAuthorship W2133176615A5008811878 @default.
• W2133176615 hasAuthorship W2133176615A5015032522 @default.
• W2133176615 hasAuthorship W2133176615A5017486273 @default.
• W2133176615 hasAuthorship W2133176615A5022620505 @default.
• W2133176615 hasAuthorship W2133176615A5031211618 @default.
• W2133176615 hasAuthorship W2133176615A5032316254 @default.
• W2133176615 hasAuthorship W2133176615A5047641886 @default.
• W2133176615 hasAuthorship W2133176615A5049309445 @default.
• W2133176615 hasAuthorship W2133176615A5050180409 @default.
• W2133176615 hasAuthorship W2133176615A5051196993 @default.
• W2133176615 hasAuthorship W2133176615A5057460230 @default.
• W2133176615 hasAuthorship W2133176615A5057763735 @default.
• W2133176615 hasAuthorship W2133176615A5068131579 @default.
• W2133176615 hasAuthorship W2133176615A5068328534 @default.
• W2133176615 hasAuthorship W2133176615A5073579921 @default.
• W2133176615 hasAuthorship W2133176615A5076446601 @default.
• W2133176615 hasConcept C126322002 @default.

• next